Jasper Therapeutics Ownership
| JSPR Stock | USD 2.33 0.04 1.69% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 15 M | Current Value 15.3 M | Avarage Shares Outstanding 12 M | Quarterly Volatility 9.5 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jasper Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. Jasper Stock Ownership Analysis
About 52.0% of the company shares are owned by institutional investors. The book value of Jasper Therapeutics was currently reported as 1.45. The company recorded a loss per share of 6.05. Jasper Therapeutics had not issued any dividends in recent years. The entity had 1:10 split on the 4th of January 2024. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It is also developing engineered hematopoietic stem cells product candidates to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Jasper Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 35 people. To learn more about Jasper Therapeutics call Ronald Martell at 650 549 1400 or check out https://jaspertx.com.Besides selling stocks to institutional investors, Jasper Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Jasper Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Jasper Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Jasper Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Jasper Therapeutics Insider Trades History
Only 1.04% of Jasper Therapeutics are currently held by insiders. Unlike Jasper Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Jasper Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Jasper Therapeutics' insider trades
Jasper Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Jasper Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Jasper Therapeutics backward and forwards among themselves. Jasper Therapeutics' institutional investor refers to the entity that pools money to purchase Jasper Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2025-06-30 | 416.3 K | Citadel Advisors Llc | 2025-06-30 | 410.4 K | Bank Of America Corp | 2025-06-30 | 293.5 K | Goldman Sachs Group Inc | 2025-06-30 | 249.8 K | Blackrock Inc | 2025-06-30 | 225.6 K | Deutsche Bank Ag | 2025-06-30 | 160 K | Bank Of Montreal | 2025-06-30 | 158.1 K | Bmo Capital Markets Corp. | 2025-06-30 | 158.1 K | Lion Point Capital, Lp | 2025-06-30 | 146.5 K | Soleus Capital Management, L.p. | 2025-06-30 | 1.5 M | Velan Capital Investment Management Lp | 2025-06-30 | 1.4 M |
Jasper Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Jasper Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Jasper Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Jasper Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Jasper Therapeutics Outstanding Bonds
Jasper Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Jasper Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Jasper bonds can be classified according to their maturity, which is the date when Jasper Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Pair Trading with Jasper Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Jasper Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Jasper Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Jasper Stock
Moving against Jasper Stock
| 0.81 | PTCT | PTC Therapeutics | PairCorr |
| 0.79 | RPTX | Repare Therapeutics | PairCorr |
| 0.69 | RLAY | Relay Therapeutics | PairCorr |
| 0.66 | XNCR | Xencor Inc | PairCorr |
| 0.6 | EDSA | Edesa Biotech | PairCorr |
The ability to find closely correlated positions to Jasper Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Jasper Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Jasper Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Jasper Therapeutics to buy it.
The correlation of Jasper Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Jasper Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Jasper Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Jasper Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Jasper Stock Analysis
When running Jasper Therapeutics' price analysis, check to measure Jasper Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jasper Therapeutics is operating at the current time. Most of Jasper Therapeutics' value examination focuses on studying past and present price action to predict the probability of Jasper Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jasper Therapeutics' price. Additionally, you may evaluate how the addition of Jasper Therapeutics to your portfolios can decrease your overall portfolio volatility.